type 2 diabetic patients with old myocardial infarction
Conditions
Interventions
Group receiving sitagliptin
Group receiving voglibose
Sponsors
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, MUSIC FAIR Project Office
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with type 2 diabetes who had received diet and exercise therapy or diet, exercise and pharmacologic therapy with oral antidiabetic agents for more than 2 months and whose blood glucose have not been sufficiently controlled (6.5%<=HbA1c [NGSP]<9.0%) 2. Patients with myocardial infarction former more than 6 months and stable condition at registration 3. Patients aged >=20 years 4. Patients who have given written informed consent to participate in the study
Exclusion criteria
Exclusion criteria: 1. Patients with type 1 diabetes 2. Patients who had a history of severe ketosis, diabetic coma or precoma within 6 mnths 3. Patients who had a history of acute myocardial infarction and unstable angina 4. Patients who had a history of coronary bypass surgery, prosthetic replacement and pacemaker implantation 5. Patients with severe heart failure (NYHA IV) 6. Patients with transient and persistent atrial fibrillation 7. Patients before or after operation, and those with severe infections or serious injury 8. Pregnant, possible pregnant, or lactating women 9. Patinets with severe kidney dysfunction (eGFR: <30mL/min or patients under dialysis) 10. Patients with severe liver dysfunction 11. Patients that cardiac MRI is contraindicated 12. Patients receiving insulin or GLP-1 receptor analogues injection 13. Patients receiving glinide and alpha glucosidase inhibitor 14. Patients with a history of hypersensitivity to the study drug 15. Patients receiving DPP-4 inhibitor 16. Patients who are considered not eligible for the study by the attending doctor due to other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in myocardial perfusion reserve by cardiac MRI after 6 months of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Changes in myocardial fibrosis by cardiac MRI after 6 months of treatment 2. Changes in left ventricular end-diastolic volume, end-systolic volume, and ventricular mass by cardiac MRI after 6 months of treatment 3. Changes in RH-PAT index by reactive hyperemia peripheral arterial tonometry after 6 months of treatment 4. Changes in home blood pressure after 6 months of treatment 5. adverse events | — |
Countries
Japan
Contacts
Public ContactTetsushiro Takeuchi
Mie University Graduate School of Medicine Department of Cardiology and Nephrology
Outcome results
None listed